A Prospective Cohort Study for Patients With Adrenal Diseases

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03474237

Enrollment

1500

Registered

2018-03-22

Start date

2018-10-01

Completion date

2027-12-31

Last updated

2020-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal Adenoma, Adrenal Incidentaloma, Adrenocortical Carcinoma, Cushing Syndrome, Pheochromocytoma, Primary Hyperaldosteronism

Keywords

algorithms, adrenal adenoma, cushing syndrome, pheochromocytoma, adrenal incidentaloma, adreocortical carcinoma, primary hyperaldosteronism

Brief summary

The purpose of this study is to investigate the pathologic features, complications, and prognostic factors of functioning adrenal adenoma and suggest follow-up algorithms for adrenal incidentaloma.

Detailed description

The investigators will recruit 150 patients annually for 10 years (adrenal incidentaloma 100 patients, pheochromocytoma 15 patients, primary aldosteronism 25 patients, adrenal cushing syndrome 10 patients, adrenocortical carcinoma 2 patients) and perform hormonal, biochemical, imaging exam according to each disease's clinical guidelines. Based on this, the investigators will identify pathologic features, complications, and prognostic factors of each disease.

Interventions

OTHERHormone study and Imaging study

1. Blood (basal hormone and follow up hormone study) 2. Imaging examination including computed tomography scan or magnetic resonance imaging

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults, male or female aged 19 years or older * newly diagnosed with adrenal disease such as adrenal incidentaloma, pheochromocytoma, primary aldosteronism, adrenal cushing syndrome, adrenocortical carcinoma

Exclusion criteria

* previous or current history of adrenal diseases * using oral or intravenous steroids * history of major depressive disorder * history of chronic alcoholics * history of any cancer with suspicious adrenal metastasis * those with acute illness (ex- patients with acute coronary syndrome within 4 weeks, acute febrile disease)

Design outcomes

Primary

Measure	Time frame	Description
Number of participants in remission	Up to 10 years	Remission rate

Secondary

Measure	Time frame	Description
Complication of adrenal disease	Up to 10 years	all complications including deaths

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026